Full Text Journal Articles from
Abstract 33559413

Advertisement

Find full text journal articles








A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01).

PMID: 33559413 (view PubMed database entry)
DOI: 10.3802/jgo.2021.32.e31 (read at publisher's website )
PMCID: PMC7930449 (free full text version available)

Download PDF Download PDF

Yong Jae Lee, Myong Cheol Lim, Byoung Gie Kim, Natalie Yl Ngoi, Chel Hun Choi, Sang Yoon Park, David Sp Tan, Yunjung Go, Jung Yun Lee,

<h4>Background</h4>The optimal treatment of <i>BRCA</i> wild-type patients with platinum-sensitive recurrent ovarian cancer remains unknown. Recently, there is an increase in the evidence to support the role of the combination of a poly(adenosine diphosphate-ribose) polymerase inhibitor, anti-angiogenic agents, and immunotherapy as maintenance therapy in <i>BRCA</i> wild-type patients with platinum-sensitive recurrence. We hypothesized that adding pembrolizumab and bevacizumab to olaparib maintenance can increase progression-free survival (PFS) in <i>BRCA</i> wild-type patients with platinum-sensitive recurrent ovarian cancer.<h4>Methods</h4><i>BRCA</i> wild-type patients who received two previous courses of platinum-containing therapy, achieved complete or partial response to last treatment, and the treatment-free interval is >6 months after the penultimate platinum-based chemotherapy offered olaparib maintenance with pembrolizumab and bevacizumab. Forty-four patients will be included from 4 sites across Singapore and Korea. The primary endpoint of the study is 6-month PFS rate.<h4>Trial registration</h4>ClinicalTrials.gov Identifier: NCT04361370, Clinical Research Information Service Identifier: KCT0005144.

J Gynecol Oncol (Journal of gynecologic oncology)
[2021, 32(2):e31]

Cited: 0 times

AltMetric Statistics

Additional resources:




Advertisement

Disclaimer
0.502 s